Efficacy of Xiyanping in the Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease and Its Effect on the Expression of GDF-15 and HIF-1α in Serum

Jun Xia Wang,1 Ying Zhang,2 Shu Fang Wang,3 Juan Li,4 and Peng Cheng Li3

1Pharmacy Department of Shijiazhuang Eighth Hospital, China
2Department of Anesthesiology, Shijiazhuang Eighth Hospital, China
3Department of Internal Medicine of Tang County Hospital of Traditional Chinese Medicine, China
4Department of Internal Medicine, Langfang Hospital of Traditional Chinese Medicine, China

Correspondence should be addressed to Ying Zhang; zy15303119869@163.com

Received 15 August 2022; Revised 24 August 2022; Accepted 17 September 2022; Published 12 October 2022

Background. COPD is a chronic respiratory disease with a long course and recurrent characteristics. According to relevant statistics, the global incidence of COPD is more than 30%, which seriously affects the life of patients and endangers their health. Objective. To observe the curative effect of Xiyanping in elderly patients with COPD and its influence on the expressions of growth differentiation GDF-15 and HIF-1α in serum. Methods. From August 2019 to December 2021, 86 elderly patients with acute exacerbation of COPD were admitted to our hospital. As the research objects, they were divided into the control group (n = 43) and the observation group (n = 43) randomly. The control group received the conventional treatment, while the observation group got Xiyanping on the basis of the control group. The differences in the duration of antibiotic use, expectoration, hospital stays, adverse reactions and serum-related factors, blood routine, pulmonary function, airway hyperreactivity index, COPD assessment test (CAT) score, and Borg score were made a comparison between them. Results. On the 3rd and 7th days after being treated, the sputum excretion in them was higher than before, but on the 3rd day of treatment, the sputum excretion in the observation group was higher than that in the control group, while on the 7th day of treatment, the sputum excretion was lower than that in the control group with statistically significant differences (P < 0.05). Before treatment, the serum-related factors and blood routine indexes between them were similar (P > 0.05). After treatment, GDF-15, HIF-1α, CXCL12, TNF-α, IL-8, TGF-β, WBC, and NEU in them were significantly lower than before, and the values in the observation group were significantly lower than those in the control group with statistically significant differences (P < 0.05). There was no difference in the related indexes of pulmonary function and airway hyperreactivity between them before treatment. After being treated, FEV1, FVC, and FEV1/FVC in them were significantly higher than those before treatment. The airway resistance and lung compliance of the two groups at exhalation and inspiration were significantly lower than before, and the values in the observation group were significantly lower than those in the control group (P < 0.05). There was no difference in CAT and Borg scores between them before treatment. After treatment, the CAT score and Borg score of these patients were significantly lower than those before treatment, and the value of the observation group was significantly lower than that of the control group (P < 0.05). Conclusion. Xiyanping can improve pulmonary function of elderly patients with acute exacerbation of COPD, reduce the response of airway hyperreactivity, and promote the excretion of sputum.
1. Introduction

Chronic obstructive pulmonary disease (COPD) in the elderly is a common clinical respiratory disease, featured by incompletely reversible airflow limitation, and the disease develops in a progressive way [1]. As a risk factor for acute exacerbation of COPD, infection can aggravate cough, increase sputum volume, and result in dyspnea [2, 3]. Infection control is a key measure in the treatment of acute exacerbation of elderly COPD. At present, antibiotics are generally used in clinical treatment, but the long-term application of antibiotics can cause drug-resistant strains, leading to flora imbalance and fungal infection [4].

According to the theory of traditional Chinese medicine, COPD belongs to “lung distension,” “asthmatic cough,” and phlegm blockages in lung collateral, accompanied by exogenous pathogenic qi, causing the stasis of heat-phlegm [4]. Xiyanping is a traditional Chinese medicine injection extracted and refined from Andrographis paniculata with antibacterial, antiviral, and other pharmacological effects, and it is widely used in infectious diseases such as bronchitis, tonsillitis, and bacterial diseases [5]. However, the studies on the efficacy of Xiyanping in COPD were few. The study is aimed at observing the influence of Xiyanping in elderly patients with COPD and its effect on the expression of GDF-15 and HIF-1α in serum. The report is as follows.

1.1. Core Tips. In this study, we found that Xiyanping could improve the pulmonary function of elderly patients with acute exacerbation of COPD, reduce the response of airway hyperreactivity, and promote the excretion of sputum, which might be related to the regulation of GDF-15 and HIF-1α-related factors.

2. Data and Methods

2.1. General Information. This study has been approved by the ethics committee. Diagnostic criteria in line with the standard of Chronic Obstructive Pulmonary Disease Diagnosis and Treatment Guidelines (2013 revision) [6] include (1) patients with COPD clinical symptoms, (2) patients who have a contact history of risk factors (including environmental factors and host factors), (3) FEV1/FVC that achieved 60%–80% after using a bronchodilator, and (4) chest X-ray/CT examination that showed increased lung texture, increased chest diameter, and increased lung field transparency.

Acute exacerbation of COPD was in line with the standard of AECOPD Diagnosis and Treatment of Chinese Expert Consensus (2017 update) [7]; (1) continuous deterioration of respiratory symptoms and (2) it is necessary to change the drug treatment plan.

2.2. Case Selection. Inclusion criteria include (1) meeting the criteria for acute exacerbation of COPD, (2) ages from 60 to 85 years without gender restriction, (3) excluding the related symptoms caused by tuberculosis and bronchiectasis, (4) patients and their families who agreed to join this study, and (5) complete clinical data.

Exclusion criteria include (1) in situ or metastatic lung cancer; (2) with previous history of pulmonary resection; (3) patients with defects in immune function; (4) bedridden or mobility-impaired patients; (5) patients with severe heart, liver, or kidney dysfunction; and (6) mental diseases.

2.3. Collection of Cases. From August 2019 to December 2021, 86 elderly patients with acute exacerbation of COPD admitted to our hospital were confirmed with the inclusion and exclusion criteria and were selected as the research subjects. As the research objects, they were divided into the control group (n = 43) and the observation group (n = 43) randomly. After the statistical test, it was found that the general information of them was balanced.

2.4. Method. The control group was given conventional treatment, including oxygen therapy, ambroxol phlegm, β2 receptor agonist bronchodilator, inhaled corticosteroids anti-inflammatory, broad-spectrum antibiotics, and other comprehensive treatment.

Based on the control group, the observation group was treated with Xiyanping injection (produced by China Jiangxi Qingfeng Pharmaceutical Co., Ltd., specification: 5 mL: 125 mg, SEDA approval number Z20026249). A total of 250 mg Xiyanping was added into 0.9% sodium chloride injection 250 mL for intravenous drip, one time per day. The two groups were evaluated after 14 days of treatment.

2.5. Detection Method. Before and after treatment, 10 mL of fasting venous blood samples was taken from patients with an empty stomach and divided into two vacuum blood vessels. One was detected by the Shenzhen Mairui five classification blood cell analyzer to test the blood routine for recording the levels of white blood cell count (WBC) and neutrophil ratio (NEU). The other one was centrifuged within 1 hour after blood collection with the rotating speed of 3500 r/min for 10 minutes. The serum was taken to detect GDF-15, HIF-1α, CXCL12, TNF-α, IL-8, and TGF-β by ELISA. The kits were all products of Shanghai Enzyme-Linked Biotechnology Co., Ltd., and the instrument was the Shenzhen Mairui RT-96A microplate reader.

Before and after treatment, CHEST GRAPHHI-10 Jester pulmonary function instrument was used to detect forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) and calculate FEV1/FVC in them. The BUXCO FinePointe RC lung compliance measurement system was used to detect airway resistance and lung compliance during exhalation and inspiration of airway hyperreactivity-related indexes in two groups.

2.6. Scoring Standard. Chronic obstructive pulmonary assessment test (CAT) score [8]: the evaluation is mainly aimed at the influence of patients’ health and daily life with a total of eight items for the range from 0 to 40. The high or low score indicated that the influence of disease on health and daily life was large or small.

Borg score [9]: the degree of dyspnea was mainly evaluated, including blood oxygen saturation, heart rate, blood pressure, and respiratory frequency from the range of 0 to 10. The scores indicated the degree of dyspnea.
2.7. Statistical Method. Professional SPSS19.0 software was used for data processing; GDF-15, HIF-1α, lung function indicators, and other data which were in accordance with normal distribution should be described by \( \bar{X} \pm s \); the \( t \)-test was used for comparison, count data was described by \( n \) (%), and the \( \chi^2 \)-test was used for comparison, with statistical significance \((P < 0.05)\).

3. Results

3.1. Differences in General Data between Two Groups. The process of the disease, the severity of illness, complications and smoking, age, and other general information were compared between the two groups, and there was no statistical difference \((P > 0.05)\) (see Table 1).

3.2. Comparison of Sputum Excretion between Two Groups. There was nothing different in sputum excretion between them before treatment. On the 3rd and 7th days after being treated, the sputum excretion in them was higher than before, but on the 3rd day of treatment, the sputum excretion in the observation group was higher than that in the control group, while on the 7th day of treatment, the sputum excretion was lower than that in the control group with a statistically significant difference \((P < 0.05)\) (see Table 2 and Figure 1).

3.3. Difference in Serum-Related Factors such as GDF-15 and HIF-1α between Two Groups. There was no difference in serum-related factors such as GDF-15 and HIF-1α between them before treatment. After treatment, GDF-15, HIF-1α, CXCL12, TNF-α, IL-8, and TGF-β in them were significantly lower than before, and the values in the observation group were significantly lower than those in the control group (see Table 3).

3.4. Difference in Blood Routine Indexes between Two Groups. There was nothing different in blood routine indexes between them before treatment. After treatment, WBC and NEU in them were significantly lower than before, and values in the observation group were significantly lower than those in the control group (see Table 4).

3.5. Difference in Pulmonary Function Indexes between Two Groups. There was nothing different in pulmonary function indexes between them before treatment. After treatment, FEV1, FVC, and FEV1/FVC in them were significantly higher than before, and the values in the observation group were significantly higher than those in the control group with statistically significant differences \((P < 0.05)\) (see Table 5).

3.6. Differences in Airway Hyperreactivity Indicators between the Two Groups. There was nothing different in the related indexes of airway hyperreactivity between them before treatment. After being treated, airway resistance and lung compliance of them at exhalation and inspiration were significantly lower than before, and the values in the observation group were significantly lower than those in the control group with a statistically significant difference \((P < 0.05)\) (see Table 6).

3.7. Differences in CAT and Borg Scores between the Two Groups. There was nothing different in the CAT score and Borg score between them before treatment. After being treated, the CAT score and Borg score of them were significantly lower than before, and the value of the observation group was significantly lower than that of the control group with a statistically significant difference \((P < 0.05)\) (see Table 7).

3.8. Differences in Duration of Antibiotic Use, Hospital Stays, and Adverse Reactions between the Two Groups. The duration of antibiotic use and hospital stays in the observation group were significantly shorter than those of the control group, while compared with the control group, there were no significant differences in the incidence of adverse reactions \((P > 0.05)\) (see Table 8).

4. Discussion

An epidemiological survey shows that COPD ranks the sixth leading reason for death among the world’s population and ranks 3rd among the causes of death from diseases in China. At present, there are about 100 million COPD patients in China, including about 30 million patients over 60 years old [10]. When they suffered from cold, infection, and inhalation of harmful gases, the symptoms would aggravate. In severe cases, respiratory failure and even death can occur [11]. At present, the routine treatment of western medicine for acute exacerbation of COPD can alleviate the clinical symptoms to some extent. However, the drug resistance of antibiotics makes the lower respiratory tract infection of a considerable number of patients unable to be effectively controlled; thus, it is difficult to achieve the ideal therapeutic effect [12].

According to the theory of traditional Chinese medicine, pathogenic qi which causes diseases invades the lung. The improper treatment leads to retention of pathogenic qi, and accumulation of phlegm and blood stasis damages healthy qi. Once the body is attacked by pathogenic qi, the sputum and blood stasis in the body will be invoked to aggravate cough and asthma. The therapeutic doctrine is heat-clearing and detoxifying, resolving phlegm, and relieving cough [13]. Xiyanping is a traditional Chinese medicine injection, and its active component is andrographolide sulfate which was prepared by sulfonation of the extract from Andrographis paniculata leaves. The in vitro antibacterial experiments showed that it had obvious inhibitory effects on adenovirus, influenza virus, respiratory syncytial virus, and pathogenic microorganisms such as Staphylococcus aureus, Streptococcus, pneumococcal bacteria, and Escherichia coli. It is currently widely used in the treatment of respiratory and intestinal infectious diseases [14, 15].

In this study, it was found that the sputum excretion of the patients treated with Xiyanping adjuvant therapy was higher than that of the patients with conventional treatment 3 days later, while on the 7th day of treatment, the sputum
excretion was lower than that in the control group. The CAT score and Borg score were lower than those of conventional treatment, and the duration of antibiotic use and hospital stays in the observation group were significantly shorter than those of the control group, while the incidence of adverse reactions in the two groups was similar. These results suggest that Xiyanping can not only better promote sputum excretion in elderly patients with acute exacerbation of COPD, reduce the symptom of dyspnea, accelerate the recovery process, and decrease the application of antibiotics but also not increase the risk of adverse reactions. Pulmonary function and airway responsiveness are clinical indicators for judging the severity and prognosis of COPD. In this study, it was found that FEV1, FVC, and FEV1/FVC of patients with Xiyanping adjuvant therapy after treatment were higher than those with conventional therapy, and their airway resistance and lung compliance during exhalation and inspiration were lower than those of patients with conventional therapy, suggesting that Xiyanping was conducive to improve lung function and reduce airway hyperreactivity.

| Normal information                                      | Control group (n = 43) | Observation group (n = 43) | χ² or t | P      |
|---------------------------------------------------------|------------------------|----------------------------|---------|--------|
| Gender (n (%))                                          |                        |                            |         |        |
| Male                                                    | 24 (55.81)             | 26 (60.47)                 | 0.191   | 0.662  |
| Female                                                  | 19 (44.19)             | 17 (39.53)                 |         |        |
| Age (x ± s)                                             | 68.96 ± 5.77           | 69.21 ± 5.23               | 0.211   | 0.834  |
| BMI (x ± s) (kg/m²)                                     | 22.33 ± 2.16           | 21.98 ± 2.24               | 0.738   | 0.463  |
| Severity of illness (n (%))                             |                        |                            |         |        |
| Moderate                                                | 32 (74.42)             | 29 (67.44)                 | 0.508   | 0.476  |
| Severe                                                  | 11 (25.58)             | 14 (32.56)                 |         |        |
| COPD course of disease (x ± s) (year)                   | 10.25 ± 3.11           | 10.08 ± 2.98               | 0.259   | 0.796  |
| Smoking status (n (%))                                  |                        |                            |         |        |
| None                                                    | 24 (55.81)             | 21 (48.84)                 | 0.426   | 0.808  |
| Quit smoking                                            | 8 (18.60)              | 9 (20.93)                  |         |        |
| Smoking                                                 | 11 (25.58)             | 13 (30.23)                 |         |        |
| Concomitant disease (n (%))                             |                        |                            |         |        |
| Hypertension                                            | 17 (39.53)             | 20 (46.51)                 | 0.427   | 0.514  |
| Diabetes                                                | 15 (34.88)             | 12 (27.91)                 | 0.486   | 0.486  |
| Coronary heart disease                                  | 12 (27.91)             | 16 (37.21)                 | 0.847   | 0.357  |
| Hyperlipidemia                                          | 18 (41.86)             | 17 (39.53)                 | 0.048   | 0.826  |

Table 2: Comparison of expectoration between the two groups.

| Group                  | n   | Before therapy  | Expectation (x ± s) (mL) | Treatment 3 d | Treatment 7 d |
|------------------------|-----|----------------|--------------------------|---------------|---------------|
| Control group          | 43  | 28.65 ± 7.46   | 74.11 ± 12.41*           | 86.32 ± 14.79*|               |
| Observation group      | 43  | 27.91 ± 8.03   | 105.45 ± 15.63*          | 34.55 ± 9.45* |               |
| t                      | 0.443| 10.297         | 19.342                   |               |               |
| P                      | 0.659| <0.001         | <0.001                   |               |               |

Compared with before treatment, *P < 0.05.

Figure 1: Comparison of sputum excretion between the two groups. Before therapy, they were similar in the two groups. On the 3rd day after treatment, the sputum excretion of the observation group was higher than that of the control group. On the 7th day after treatment, the sputum excretion of the observation group was lower than that of the control group.
prevents the proliferation and replication of viruses and bacteria by preventing protein from wrapping DNA fragments, protects lysosome membrane, reduces capillary synthesis, and enhances antibacterial activity by introducing hydrophilic groups into the structure of andrographolide, thus protecting elderly patients with acute exacerbation of COPD. By introducing hydrophilic groups into the structure of andrographolide to enhance its antibacterial activity, Xiyanping prevents the proliferation and replication of viruses and bacteria by preventing protein from wrapping DNA fragments, protects lysosome membrane, reduces capillary permeability, and improves cellular immune function [16, 30].

Table 3: Differences in serum-related factors such as GDF-15 and HIF-1α between them (\(\bar{x} \pm s\)).

| Group          | n  | GDF-15 (μg/L) Before | After | HIF-1α (ng/L) Before | After | CXCL12 (ng/L) Before | After |
|----------------|----|----------------------|-------|----------------------|-------|----------------------|-------|
| Control group  | 43 | 2.85 ± 0.49          | 1.65 ± 0.38* | 30.58 ± 8.99       | 18.11 ± 6.43* | 314.52 ± 74.96    | 274.63 ± 54.14* |
| Observation group | 43 | 2.79 ± 0.55          | 1.21 ± 0.27* | 29.97 ± 9.07       | 11.42 ± 4.45* | 305.88 ± 79.11    | 213.52 ± 43.63* |
| t              |    | 0.534                | 6.190  | 0.313                | 5.610  | 0.520                | 5.763  |
| P              |    | 0.595                | <0.001 | 0.755                | <0.001 | 0.605                | <0.001 |

Compared with before treatment, *P < 0.05.

Table 4: Differences in blood routine indexes between the two groups (\(\bar{x} \pm s\)).

| Group          | n  | WBC (χ10^9/L) Before | After | NEU (%) Before | After |
|----------------|----|----------------------|-------|----------------|-------|
| Control group  | 43 | 12.23 ± 2.89         | 8.87 ± 1.97* | 87.45 ± 8.63    | 76.64 ± 6.49* |
| Observation group | 43 | 12.31 ± 2.57         | 7.18 ± 1.54* | 85.97 ± 8.44    | 69.85 ± 5.14* |
| t              |    | 0.136                | 4.432  | 0.804           | 5.378  |
| P              |    | 0.892                | <0.001 | 0.424           | <0.001 |

Compared with before treatment, *P < 0.05.

Table 5: Differences in pulmonary function indexes between the two groups (\(\bar{x} \pm s\)).

| Group          | n  | FEV1 (L) Before | After | FVC (L) Before | After | FEV1/FVC (%) Before | After |
|----------------|----|----------------|-------|----------------|-------|---------------------|-------|
| Control group  | 43 | 1.21 ± 0.49    | 1.68 ± 0.52* | 2.04 ± 0.59    | 2.46 ± 0.61* | 53.25 ± 8.47        | 66.56 ± 7.56* |
| Observation group | 43 | 1.23 ± 0.43    | 2.19 ± 0.61* | 2.11 ± 0.58    | 2.89 ± 0.64* | 55.04 ± 8.29        | 75.48 ± 6.04* |
| t              |    | 0.201          | 4.172  | 0.555          | 3.189  | 0.990               | 6.045  |
| P              |    | 0.841          | <0.001 | 0.580          | 0.002  | 0.325               | <0.001 |

Compared with before treatment, *P < 0.05.

Table 6: Differences in airway hyperreactivity indicators between the two groups (\(\bar{x} \pm s\)).

| Group          | n  | Airway resistance during exhalation (cm H2O/(L·s)) Before | After | Airway resistance during inspiration (cm H2O/(L·s)) Before | After | Lung compliance (mL/cm H2O) Before | After |
|----------------|----|--------------------------------------------------------|-------|----------------------------------------------------------|-------|----------------------------------|-------|
| Control group  | 43 | 1.87 ± 0.74                                           | 1.42 ± 0.51* | 1.81 ± 0.89                                           | 1.54 ± 0.41* | 174.25 ± 45.36                  | 135.26 ± 31.05* |
| Observation group | 43 | 1.89 ± 0.69                                           | 1.21 ± 0.43* | 1.86 ± 0.82                                           | 1.28 ± 0.37* | 169.85 ± 48.14                  | 108.57 ± 24.96* |
| t              |    | 0.130                                                  | 2.064  | 0.271                                                   | 3.087  | 0.436                            | 4.393  |
| P              |    | 0.897                                                  | 0.042  | 0.787                                                   | 0.003  | 0.664                            | <0.001 |

Compared with before treatment, *P < 0.05.
treated with Xiyanping adjuvant therapy was significantly lower than that in the patients treated with conventional therapy, suggesting that Xiyanping could regulate GDF-15 and HIF-1α to other inflammatory-related factors and reduce the inflammatory response of the body, which was one of the important mechanisms in the treatment of acute exacerbation of COPD in the elderly by detecting the above inflammatory indexes.

There were some limitations of this study. The sample size was limited. And this study was conducted in only one hospital. Thus, the results need to be confirmed by a multicenter randomized controlled study with a large cohort.

In summary, Xiyanping could improve the pulmonary function of elderly patients with acute exacerbation of COPD, reduce the response of airway hyperreactivity, and promote the excretion of sputum.

### Data Availability

The datasets used and analyzed during the current study are available from the corresponding author upon reasonable request.

### Conflicts of Interest

The authors declare that they have no conflicts of interest.

### Authors’ Contributions

Jun Xia Wang and Ying Zhang did the same work as the co-first author. Jun Xia Wang and Ying Zhang have contributed equally to this work and share the first authorship.

### Acknowledgments

The study was funded by the Project of Hebei Administration of Traditional Chinese Medicine, No.: 2020292.

### References

[1] A. Kichloo, M. Aljadah, N. Vipparla, and F. Wani, "Optimal glucocorticoid dose and the effects on mortality, length of stay,

| Table 7: Differences in CAT scores and Borg scores between the two groups ((x ± s), fraction). |
|------------------------------|------------------|------------------|------------------|------------------|
| Group                        | n    | Before CAT score | After CAT score | Before Borg score | After Borg score |
|------------------------------|------|------------------|------------------|------------------|------------------|
| Control group                | 43   | 17.05 ± 5.94     | 11.89 ± 2.16*    | 8.87 ± 2.07      | 6.13 ± 1.88*     |
| Observation group            | 43   | 16.53 ± 6.17     | 9.23 ± 2.07*     | 8.95 ± 2.13      | 4.57 ± 1.29*     |
| t                            | 0.398| 5.830            | 0.177            | 4.487            |
| P                            | 0.692| <0.001           | 0.860            | <0.001           |

Compared with before treatment, *P < 0.05.

| Table 8: Differences in duration of antibiotic use, length of stay, and adverse reactions between the two groups. |
|------------------------------|------------------|------------------|------------------|------------------|
| Group                        | n    | Antibiotic use time (x ± s) (d) | Hospital stay (x ± s) (d) | Adverse reactions (%)) (a) | Rash | Diarrhea | Irritable | Total |
|------------------------------|------|------------------|------------------|------------------|------|----------|------------|-------|
| Control group                | 43   | 8.47 ± 1.89      | 13.07 ± 2.57     | 1 (2.33)         | 2 (4.65) | 0 (0.00) | 3 (6.98)   |
| Observation group            | 43   | 6.35 ± 1.41      | 9.84 ± 1.93      | 1 (2.33)         | 1 (2.33) | 4 (9.30)  | 0.156      |
| t or χ²                      | 5.896| 6.590            | 4 (9.30)         | 1 (2.33)         | 4 (9.30) | 0.156     | 0.693      |
| P                            | <0.001| <0.001           |                  |                  | 0.000     | 0.693     |            |
and readmission rates in patients diagnosed with acute exacerbation of chronic obstructive pulmonary disease (AECOPD)," Journal of Investigative Medicine, vol. 67, no. 8, pp. 1161–1164, 2019.

[2] J. G. Lin, J. Lyu, M. H. Sun, X. Liao, and Y. M. Xie, "Systematic review and meta-analysis of shenfu injection on treating acute exacerbation of chronic obstructive pulmonary disease," World Journal of Traditional Chinese Medicine, vol. 6, no. 3, pp. 276–283, 2020.

[3] A. Singanayagam, S. L. Loo, M. Calderazzo et al., "Antiviral immunity is impaired in COPD patients with frequent exacerbations," American Journal of Physiology, vol. 317, no. 6, pp. L893–L903, 2019.

[4] W. Yd, Z. Li, and L. Fs, "Study on the distribution of TCM constitution in patients with stable chronic obstructive pulmonary disease," World Chinese medicine, vol. 16, no. 23, pp. 3532–3538, 2021.

[5] Q. Zhao, W. Lq, Z. Xq, Y. Zh, S. Sl, and Z. Xiong, "The efficacy of Xiyangping combined with levofloxacin in the treatment of lower respiratory tract bacterial infection in acute exacerbation of COPD," Hainan Medical, vol. 30, no. 18, pp. 2412–2414, 2019.

[6] Chronic obstructive pulmonary disease group, respiratory disease branch of Chinese Medical Association, Guidelines for the Diagnosis and Treatment of Chronic Obstructive Pulmonary Disease (2013 Revision), vol. 6, no. 5, 2013General practice clinical and education, 2013.

[7] Expert group on diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD), "Chinese expert consensus on the diagnosis and treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) (updated in 2017)," International Journal of Respiratory Medicine, vol. 37, no. 14, pp. 1041–1057, 2017.

[8] T. Yh and F. Gh, "The application of chronic obstructive pulmonary disease assessment test in the efficacy evaluation of patients with acute exacerbation," Chinese Journal of Tuberculosis and Respiratory, vol. 37, no. 1, pp. 56–57, 2014.

[9] Z. Xn and Y. Ly, "Evaluation of mechanical ventilation in patients with acute exacerbation of chronic obstructive pulmonary disease by four grades," International Journal of Respiratory Medicine, vol. 39, no. 16, pp. 1226–1230, 2019.

[10] M. I. Abas, M. Z. Zubir, M. F. Ishak et al., "Patients characteristics and outcomes analysis of COPD readmissions in a teaching Hospital in Kuala Lumpur, Malaysia," International medical journal IMJ, vol. 27, no. 6, pp. 705–708, 2020.

[11] A. Salarin-Moghaddam, A. Milajerdi, B. Larjani, and A. Esmaillzadeh, "Processed red meat intake and risk of COPD: a systematic review and dose-response meta-analysis of prospective cohort studies," Clinical Nutrition, vol. 38, no. 3, pp. 1109–1116, 2019.

[12] Y. Aydemir, Ö. Aydemir, A. Şengil et al., "Comparison of oxidant/antioxidant balance in COPD and non-COPD smokers," Journal of Critical Care, vol. 48, no. 6, pp. 566–569, 2019.

[13] Z. Yw, S. Ci, L. Wei, and W. Zw, "Study on the mechanism of promoting the improvement of COPD in remission stage and airway mucosal tissue repair based on TCM comprehensive treatment mode," Laboratory medicine and clinical, vol. 18, no. 7, pp. 897–900, 2021.

[14] Z. Bh, L. Zheng, H. Shao, and Y. Lp, "Rapid health technology assessment of Xiyangping injection in the treatment of respiratory diseases in children," Evaluation and aAnalysis of Drug uUse in Chinese Hospitals, vol. 22, no. 2, pp. 208–212, 2022.

[15] L. ZI, "Effect of Xiyangping combined with high flow humidiﬁed oxygen inhalation on inﬂammatory mediators and pulmonary function in patients with acute respiratory failure," Chinese medicine and clinical, vol. 21, no. 2, pp. 223–227, 2021.

[16] S. Soisuwan, V. Teenanchadeekul, A. Wongrakpanich, P. Langguth, and V. B. Junyaprasert, "Impact of unchanged and charged stabilizers on in vitro drug performances of clarithromycin nanocrystals," European Journal of Pharmaceutics and Biopharmaceutics, vol. 137, no. 7, pp. 68–76, 2019.

[17] C. M. Lee, E. H. Jung, J. Y. Byeon et al., "Effects of steady-state clarithromycin on the pharmacokinetics of zolpidem in healthy subjects," Archives of Pharmacal Research, vol. 42, no. 12, pp. 1101–1106, 2019.

[18] X. Sy, W. Li, Z. Hx, P. Pw, M. Ey, and W. Bo, "Clinical application analysis of Xiyangping aerosol inhalation in the treatment of infantile pneumonia," Chinese Journal of Clinical Pharmacology, vol. 37, no. 12, pp. 1596–1598,1602, 2021.

[19] N. Don, X. Dh, Y. Gh, R. Ning, and L. Xx, "Effect and mechanism of Xiyangping injection on serum inﬂammatory factors and whole blood bitterness receptor levels in patients with ARDS," Journal of Guizhou Medical University, vol. 46, no. 12, pp. 1433–1437,1451, 2021.

[20] S. Y. Lee, S. S. Cho, C. S. Bae, M. S. Bae, and D. H. Park, "Socheongyotang suppresses COPD-related changes in the pulmonary system through both cytokines and chemo- kines in a LPS COPD model," Pharmaceutical Biology, vol. 58, no. 1, pp. 538–544, 2020.

[21] S. Gao, Y. Duan, J. Chen, and J. Wang, "Evaluation of blood markers at admission for predicting community acquired pneumonia in chronic obstructive pulmonary disease," COPD: Journal of Chronic Obstructive Pulmonary Disease, vol. 18, no. 5, pp. 557–566, 2021.

[22] J. Huang, T. Zeng, Y. Tian et al., "Clinical significance of high-mobility group box-1 (HMGB1) in subjects with type 2 diabetes mellitus (T2DM) combined with chronic obstructive pulmonary disease (COPD)," Journal of clinical laboratory analysis, vol. 33, no. 6, pp. 910–915, 2019.

[23] K. Larissi, M. Politou, A. Margeli et al., "The growth differentiation factor-15 (GDF-15) levels are increased in patients with compound heterozygous sickle cell and beta-thalassemia (HbS/Bthal), correlate with markers of hemolysis, iron burden, coagulation, endothelial dysfunction and pulmonary hypertension," Blood cells, molecules and diseases, vol. 77, no. 7, pp. 137–141, 2019.

[24] L. Fang, F. Li, and C. Gu, "GDF-15: a multifunctional modulator and potential therapeutic target in cancer," Current Pharmaceutical Design, vol. 25, no. 6, pp. 654–662, 2019.

[25] S. D. Kriechbaum, C. B. Wiedenroth, K. Peters et al., "Galectin-3, GDF-15, and sST2 for the assessment of disease severity and therapy response in patients suffering from inoperable chronic thromboembolic pulmonary hypertension," Biomarkers, vol. 25, no. 7, pp. 578–586, 2020.

[26] L. Lin, J. Sun, D. Wu et al., "MicroRNA-186 is associated with hypoxia-inducible factor-1α expression in chronic obstructive pulmonary disease," Molecular Genetics & Genomic Medicine, vol. 7, no. 3, pp. e531–e685, 2019.

[27] S. N. Rathnayake, F. A. Hoesien, C. J. Galban et al., "Gene expression profiling of bronchial brushes is associated with the level of emphysema measured by computed tomography-based parametric response mapping," American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 318, no. 6, pp. L1222–L1228, 2020.
[28] G. F. Korytina, L. Z. Akhmadishina, O. V. Kochetova, Y. G. Aznabaeva, S. Z. Zagidullin, and T. V. Victorova, “The role of serum amyloid A1, adhesion molecules, chemokines, and chemokine receptors genes in chronic obstructive pulmonary disease,” Russian Journal of Genetics, vol. 55, no. 1, pp. 105–113, 2019.

[29] K. Nakamoto, M. Watanabe, M. Sada et al., “Pseudomonas aeruginosa-derived flagellin stimulates IL-6 and IL-8 production in human bronchial epithelial cells: a potential mechanism for progression and exacerbation of COPD,” Experimental Lung Research, vol. 45, no. 8, pp. 255–266, 2019.

[30] B. Shyam Prasad Shetty, S. K. Chaya, V. S. Kumar et al., “Inflammatory biomarkers interleukin 1 beta (IL-1β) and tumour necrosis factor alpha (TNF-α) are differentially elevated in tobacco smoke associated COPD and biomass smoke associated COPD,” Toxics, vol. 9, no. 4, p. 72, 2021.

[31] C. Mouronte-Roibás, V. Leiro-Fernández, A. Ruano-Raviña et al., “Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study,” Respiratory Research, vol. 20, no. 1, pp. 128–130, 2019.

[32] C. Ben Brahim, C. Courageux, A. Jolly et al., “Proliferation genes repressed by TGF-β are downstream of Slug/Snail2 in normal bronchial epithelial progenitors and are deregulated in COPD,” Stem Cell Reviews and Reports, vol. 17, no. 3, pp. 703–718, 2021.

[33] R. K. Dutta, S. Chinnapaiyan, L. Rasmussen, S. V. Raju, and H. J. Unwalla, “A neutralizing aptamer to TGFBR2 and miR-145 antagonism rescue cigarette smoke- and TGF-β-mediated CFTR expression,” Molecular therapy: the journal of the American Society of Gene Therapy, vol. 27, no. 2, pp. 442–455, 2019.

[34] J. A. Schrumpf, D. K. Ninaber, A. M. van der Does, and P. S. Hiemstra, “TGF-β1 impairs vitamin D-induced and constitutive airway epithelial host defense mechanisms,” Advanced Science, Engineering and Medicine, vol. 12, no. 1, pp. 74–89, 2020.